Saffron
Also sold as: Crocus sativus · Saffron stigma extract
A stigma-derived botanical studied for mood, anxiety and sleep. Extract identity matters more than the number of milligrams alone.
Anxiety Sleep
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Sleep: Small trials suggest better subjective sleep quality, with uncertain clinical magnitude.
- Anxiety: Self-reported anxiety improved in small heterogeneous trials; clinician-rated HARS did not show a significant pooled effect.
REALITY CHECK // Saffron is not a proven substitute for an antidepressant. Benefits are clearest on self-report scales, with extreme heterogeneity, short mostly Iranian trials, inconsistent extract composition and publication-bias concerns. No robust long-term safety or interaction trials resolve these gaps.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // No established numeric EFSA/NIH UL is supplied. Trial amounts are not a safety ceiling; gram quantities of raw saffron carry toxicity and pregnancy concerns, with exact toxic thresholds unverified here.
Summary
Mood findings are promising but variable. A 34-RCT meta-analysis (1,769 participants) found BDI WMD -4.39 (95% CI -6.64 to -2.15; I-squared 92.3%); clinician-rated depression and anxiety measures did not show significant benefits. Small SSRI comparisons do not establish equivalent efficacy or interchangeability.
Mechanism
Crocin is converted in the intestine to crocetin; serotonergic, antioxidant and neuronal effects are proposed. Mechanisms do not establish treatment efficacy.
Typical studied dose
Mood trials commonly used 28-30 mg/day of stigma extract for 4-8 weeks. Affron used 28 mg/day with at least 3.5% declared Lepticrosalides. Satiereal appetite research used 176.5 mg/day for 8 weeks; products are not dose-equivalent.
Upper limit
No established numeric EFSA/NIH UL is supplied. Trial amounts are not a safety ceiling; gram quantities of raw saffron carry toxicity and pregnancy concerns, with exact toxic thresholds unverified here.
Popular stacks with Saffron
Not enough stack data yet. A combination with Saffron appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Standardized stigma extract (Affron) Best for: Mood trial matching |
Extract weight · ~3.5% marker | 28–28 mg | Full extract mass is compared, not marker mass. Declared Lepticrosalides at least 3.5% is a marker specification, not pure crocin or proven clinical equivalence. Usually tolerated at studied amounts; individual gastrointestinal discomfort remains possible. |
Studied standard [FORM // TRIAL_REFERENCE] Full extract mass is compared, not marker mass. Declared Lepticrosalides at least 3.5% is a marker specification, not pure crocin or proven clinical equivalence. |
| Satiereal stigma extract Best for: Appetite research comparison |
Extract weight · marker not quantified | 176.5–176.5 mg | The appetite trial used 176.5 mg/day of extract. Marker percentage is unknown in the supplied data (0 means unknown). Usually tolerated at studied amounts; individual gastrointestinal discomfort remains possible. |
Good option [FORM // CHECK_LABEL] The appetite trial used 176.5 mg/day of extract. Marker percentage is unknown in the supplied data (0 means unknown). |
| Unbranded stigma powder Best for: Label comparison |
Unstandardized: active content unknown | no comparable trial range | Variable crocin and safranal content and adulteration risk prevent verified equivalence to branded extracts. No universal conversion is available. Usually tolerated at studied amounts; individual gastrointestinal discomfort remains possible. |
Caution [FORM // CHECK_LABEL] Variable crocin and safranal content and adulteration risk prevent verified equivalence to branded extracts. No universal conversion is available. |
Common label traps
- TRAP_01 // SAFFRON IS NATURAL PROZAC
Small trials finding no significant difference from SSRIs do not prove equivalent treatment efficacy. - TRAP_02 // ALL EXTRACT MILLIGRAMS ARE EQUIVALENT
Affron 28 mg and Satiereal 176.5 mg have different preparations and endpoints; compare the exact extract and marker specification. - TRAP_03 // MORE IS BETTER
No numeric UL is established; culinary use does not establish safety for concentrated extracts or gram quantities.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- depression Moderate · benefit
34 RCTs, n=1769: BDI WMD -4.39 (95% CI -6.64 to -2.15), but I-squared 92.3% and clinician-rated HDRS/HARS/POMS null. Moderate certainty for self-report does not establish a medication replacement.
PMID 41693488 - anxiety Limited · benefit
BAI WMD -5.06 (95% CI -8.44 to -1.68), I-squared 94.8%; clinician-rated HARS null.
PMID 41693488 - ssri-comparison Limited · benefit
Eight depression RCTs: SMD 0.10 (95% CI -0.09 to 0.29); four anxiety RCTs: 0.04 (-0.22 to 0.29). Adverse-event RD -0.06 (-0.09 to -0.04). Non-significance does not establish noninferiority.
PMID 38913392 - retinal-function Limited · benefit
Small short-term AMD/Stargardt trials suggest better retinal sensitivity; no replacement for ophthalmic care or AREDS when indicated.
PMID 20688744 PMID 30343354 PMID 31618812 - pms Limited · benefit
Small RCT using 30 mg/day over two cycles and a subsequent review suggest symptom improvement.
PMID 18271889 PMID 41151539 - adhd Limited · benefit
Small pediatric trials over 6-8 weeks suggest symptom improvement, including methylphenidate comparisons; not enough to replace established treatment.
PMID 30741567 PMID 37864351 - appetite Limited · benefit
Industry-linked trial in 60 mildly overweight women: 176.5 mg/day for 8 weeks reduced snacking and weight modestly; not a fat burner.
PMID 20579522 - sexual-function Limited · benefit
A small trial supports a signal for fluoxetine-associated sexual impairment in men. Broader erectile-function and semen findings remain mixed.
PMID 22552758 PMID 29881706 - sleep Limited · benefit
Small RCTs report subjective sleep-quality improvement, including patients with diabetes; generalizability is uncertain.
PMID 33925432 PMID 33960081 - cognitive-impairment Limited · benefit
Small trials in MCI or mild-moderate Alzheimer disease suggest cognitive improvement; this does not establish focus enhancement in healthy adults.
PMID 33167948 - mood-extract Limited · benefit
Affron studied mood in healthy adults over four weeks; extract-specific evidence does not validate all saffron products.
PMID 28735826
Reader questions
Can saffron replace my antidepressant?
No. The evidence does not justify independent substitution or discontinuation. Discuss any adjunct with the prescribing clinician.
Which dose matches the mood research?
Commonly 28-30 mg/day of a specified stigma preparation for several weeks; Satiereal appetite research used a different extract and amount.
Does it improve focus?
MCI, Alzheimer disease and pediatric ADHD studies cannot establish healthy-adult focus benefits.
Stack interactions
- Caution SSRIs/SNRIs and serotonergic supplements [CAUTION // CLINICAL_REVIEW]
Potential serotonergic addition is theoretical; saffron has also been studied as an adjunct. A psychiatrist should review combinations or medication changes.
PMID 38913392 PMID 22552758 - Caution Anticoagulants and antiplatelets [CAUTION // CLINICAL_REVIEW]
Platelet/coagulation findings motivate caution, but a clinically important drug interaction is not established. Discuss use before surgery.
PMID 23733488 PMID 16180089 PMID 18817408 - Caution Glucose-lowering and blood-pressure medication [CAUTION // CLINICAL_REVIEW]
A diabetes RCT found improved glycemic markers; additive glucose lowering is plausible. Blood-pressure interaction evidence is indirect and unverified.
PMID 33960081
Red flags: interactions and who should avoid it
Interactions
Potential serotonergic addition is theoretical; saffron has also been studied as an adjunct. A psychiatrist should review combinations or medication changes. Platelet/coagulation findings motivate caution, but a clinically important drug interaction is not established. Discuss use before surgery. A diabetes RCT found improved glycemic markers; additive glucose lowering is plausible. Blood-pressure interaction evidence is indirect and unverified.
Avoid or ask a doctor first if
Avoid supplemental extracts during pregnancy and breastfeeding. Seek review with bleeding disorders, psychiatric medication, bipolar disorder or before surgery. Pediatric ADHD data are pilot evidence, requiring specialist care. Headache, nausea, appetite changes and sedation can occur.
Sources (PubMed, 19)
- Effect of saffron on depression, anxiety and mood disorder: a GRADE assessed systematic review and meta-analysis of 34 randomized controlled trials.
PMID 41693488 · 2026 · systematic review/meta-analysis34 RCTs, n=1769: BDI WMD -4.39 (95% CI -6.64 to -2.15), but I-squared 92.3% and clinician-rated HDRS/HARS/POMS null. Moderate certainty for self-report does not establish a medication replacement.
- Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials.
PMID 38913392 · 2025 · systematic review/meta-analysisEight depression RCTs: SMD 0.10 (95% CI -0.09 to 0.29); four anxiety RCTs: 0.04 (-0.22 to 0.29). Adverse-event RD -0.06 (-0.09 to -0.04). Non-significance does not establish noninferiority.
- Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration.
PMID 20688744 · 2010 · randomized controlled trialSmall short-term AMD/Stargardt trials suggest better retinal sensitivity; no replacement for ophthalmic care or AREDS when indicated.
- Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial.
PMID 30343354 · 2019 · randomized controlled trialSmall short-term AMD/Stargardt trials suggest better retinal sensitivity; no replacement for ophthalmic care or AREDS when indicated.
- Antioxidant Saffron and Central Retinal Function in ABCA4-Related Stargardt Macular Dystrophy.
PMID 31618812 · 2019 · randomized controlled trialSmall short-term AMD/Stargardt trials suggest better retinal sensitivity; no replacement for ophthalmic care or AREDS when indicated.
- Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial.
PMID 18271889 · 2008 · randomized controlled trialSmall RCT using 30 mg/day over two cycles and a subsequent review suggest symptom improvement.
- Effect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis.
PMID 41151539 · 2026 · systematic review/meta-analysisSmall RCT using 30 mg/day over two cycles and a subsequent review suggest symptom improvement.
- Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study.
PMID 30741567 · 2019 · randomized controlled trialSmall pediatric trials over 6-8 weeks suggest symptom improvement, including methylphenidate comparisons; not enough to replace established treatment.
- The Effects of Crocus sativus (Saffron) on ADHD: A Systematic Review.
PMID 37864351 · 2024 · systematic review/meta-analysisSmall pediatric trials over 6-8 weeks suggest symptom improvement, including methylphenidate comparisons; not enough to replace established treatment.
- Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-controlled study of mildly overweight, healthy women.
PMID 20579522 · 2010 · randomized controlled trialIndustry-linked trial in 60 mildly overweight women: 176.5 mg/day for 8 weeks reduced snacking and weight modestly; not a fat burner.
- Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial.
PMID 22552758 · 2012 · randomized controlled trialA small trial supports a signal for fluoxetine-associated sexual impairment in men. Broader erectile-function and semen findings remain mixed.
- A systematic review and meta-analysis of clinical trials on saffron (Crocus sativus) effectiveness and safety on erectile dysfunction and semen parameters.
PMID 29881706 · 2018 · systematic review/meta-analysisA small trial supports a signal for fluoxetine-associated sexual impairment in men. Broader erectile-function and semen findings remain mixed.
- Effects of Saffron Extract on Sleep Quality: A Randomized Double-Blind Controlled Clinical Trial.
PMID 33925432 · 2021 · randomized controlled trialSmall RCTs report subjective sleep-quality improvement, including patients with diabetes; generalizability is uncertain.
- Saffron improves life and sleep quality, glycaemic status, lipid profile and liver function in diabetic patients: A double-blind, placebo-controlled, randomised clinical trial.
PMID 33960081 · 2021 · randomized controlled trialSmall RCTs report subjective sleep-quality improvement, including patients with diabetes; generalizability is uncertain.
- Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials.
PMID 33167948 · 2020 · systematic review/meta-analysisSmall trials in MCI or mild-moderate Alzheimer disease suggest cognitive improvement; this does not establish focus enhancement in healthy adults.
- affron® a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial.
PMID 28735826 · 2017 · randomized controlled trialAffron studied mood in healthy adults over four weeks; extract-specific evidence does not validate all saffron products.
- Effect of Crocus sativus L. (saffron) on coagulation and anticoagulation systems in healthy volunteers.
PMID 23733488 · 2014 · randomized controlled trialPlatelet/coagulation findings motivate caution, but a clinically important drug interaction is not established. Discuss use before surgery.
- Inhibition of human platelet aggregation and membrane lipid peroxidation by food spice, saffron.
PMID 16180089 · 2005 · in vitro studyPlatelet/coagulation findings motivate caution, but a clinically important drug interaction is not established. Discuss use before surgery.
- Involvement of Ca2+ in the inhibition by crocetin of platelet activity and thrombosis formation.
PMID 18817408 · 2008 · animal studyPlatelet/coagulation findings motivate caution, but a clinically important drug interaction is not established. Discuss use before surgery.
Community comments
No approved comments yet. Comments are held for moderation.